BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 27528759)

  • 1. Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH): three players for one phenotype in cancer?
    Laurenti G; Tennant DA
    Biochem Soc Trans; 2016 Aug; 44(4):1111-6. PubMed ID: 27528759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisiting the TCA cycle: signaling to tumor formation.
    Raimundo N; Baysal BE; Shadel GS
    Trends Mol Med; 2011 Nov; 17(11):641-9. PubMed ID: 21764377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The functional roles of TCA cycle metabolites in cancer.
    Eniafe J; Jiang S
    Oncogene; 2021 May; 40(19):3351-3363. PubMed ID: 33864000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inborn and acquired metabolic defects in cancer.
    Frezza C; Pollard PJ; Gottlieb E
    J Mol Med (Berl); 2011 Mar; 89(3):213-20. PubMed ID: 21301796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms.
    Schaefer IM; Hornick JL; Bovée JVMG
    Lab Invest; 2018 Apr; 98(4):414-426. PubMed ID: 29339836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase.
    Pollard PJ; Wortham NC; Tomlinson IP
    Ann Med; 2003; 35(8):632-9. PubMed ID: 14708972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial metabolic remodeling in response to genetic and environmental perturbations.
    Hollinshead KE; Tennant DA
    Wiley Interdiscip Rev Syst Biol Med; 2016 Jul; 8(4):272-85. PubMed ID: 27196610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial dysfunctions in cancer: genetic defects and oncogenic signaling impinging on TCA cycle activity.
    Desideri E; Vegliante R; Ciriolo MR
    Cancer Lett; 2015 Jan; 356(2 Pt A):217-23. PubMed ID: 24614286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of mutation of metabolism-related genes in genomic hypermethylation.
    Waterfall JJ; Killian JK; Meltzer PS
    Biochem Biophys Res Commun; 2014 Dec; 455(1-2):16-23. PubMed ID: 25111818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic alteration in tumorigenesis.
    Yang H; Xiong Y; Guan K
    Sci China Life Sci; 2013 Dec; 56(12):1067-75. PubMed ID: 24114443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting cancer metabolism.
    Teicher BA; Linehan WM; Helman LJ
    Clin Cancer Res; 2012 Oct; 18(20):5537-45. PubMed ID: 23071355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fumarate hydratase in cancer: A multifaceted tumour suppressor.
    Schmidt C; Sciacovelli M; Frezza C
    Semin Cell Dev Biol; 2020 Feb; 98():15-25. PubMed ID: 31085323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of excess succinate and retrograde control of metabolite accumulation in yeast tricarboxylic cycle mutants.
    Lin AP; Anderson SL; Minard KI; McAlister-Henn L
    J Biol Chem; 2011 Sep; 286(39):33737-46. PubMed ID: 21841001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical assays for mitochondrial activity: assays of TCA cycle enzymes and PDHc.
    Reisch AS; Elpeleg O
    Methods Cell Biol; 2007; 80():199-222. PubMed ID: 17445696
    [No Abstract]   [Full Text] [Related]  

  • 15. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer.
    King A; Selak MA; Gottlieb E
    Oncogene; 2006 Aug; 25(34):4675-82. PubMed ID: 16892081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer. Puzzling patterns of predisposition.
    Pollard PJ; Ratcliffe PJ
    Science; 2009 Apr; 324(5924):192-4. PubMed ID: 19359573
    [No Abstract]   [Full Text] [Related]  

  • 17. Genetically-defined metabolic reprogramming in cancer.
    Mullen AR; DeBerardinis RJ
    Trends Endocrinol Metab; 2012 Nov; 23(11):552-9. PubMed ID: 22858391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations.
    Pollard PJ; Brière JJ; Alam NA; Barwell J; Barclay E; Wortham NC; Hunt T; Mitchell M; Olpin S; Moat SJ; Hargreaves IP; Heales SJ; Chung YL; Griffiths JR; Dalgleish A; McGrath JA; Gleeson MJ; Hodgson SV; Poulsom R; Rustin P; Tomlinson IP
    Hum Mol Genet; 2005 Aug; 14(15):2231-9. PubMed ID: 15987702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic enzymes as oncogenes or tumor suppressors.
    Thompson CB
    N Engl J Med; 2009 Feb; 360(8):813-5. PubMed ID: 19228626
    [No Abstract]   [Full Text] [Related]  

  • 20. Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.
    Menendez JA; Alarcón T; Joven J
    Cell Cycle; 2014; 13(5):699-709. PubMed ID: 24526120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.